Post job

Daiichi Sankyo main competitors are AstraZeneca, Boehringer Ingelheim, and Janssen.

Competitor Summary. See how Daiichi Sankyo compares to its main competitors:

  • Sanofi US has the most employees (110,000).
  • Employees at AstraZeneca earn more than most of the competitors, with an average yearly salary of $112,988.
Work at Daiichi Sankyo?
Share your experience

Daiichi Sankyo vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
2005
4.8
Parsippany-Troy Hills, NJ2$9.0B15,348
1910
4.7
Shirley, NY5$52.2M350
1987
4.4
Parsippany-Troy Hills, NJ1$22.0M350
-
4.5
--$6.4B158
1997
4.7
Malvern, PA3$2.6B385
1901
4.3
Kalamazoo, MI1$130.0M350
1968
4.2
Rockaway, NJ1$105.1M3,000
1954
4.2
Saint Louis, MO1$40.0M50
1998
4.7
Deerfield, IL14$12.1B30,481
1953
4.9
Raritan, NJ4$601.4M1,500
1999
4.6
Wilmington, DE8$25.9B76,100
1973
4.3
Bridgewater, NJ1$980.0M110,000
1984
4.6
Ridgefield, CT5$17.2B52,391
2000
4.3
Newport, KY1$18.8M100
1995
4.0
Newark, CA2$342.7M494
1996
4.5
San Diego, CA1$218.0M290
1928
4.3
Smyrna, GA3$5.7B7,600
1985
4.3
Fairfield, NJ1$145.0M300
2001
4.7
Somerset, NJ1$80.0M149
1996
3.8
Morristown, NJ1$146.1M171
2011
3.9
Alpharetta, GA1$11.0M206

Rate how well Daiichi Sankyo differentiates itself from its competitors.

Zippia waving zebra

Daiichi Sankyo salaries vs competitors

Among Daiichi Sankyo competitors, employees at AstraZeneca earn the most with an average yearly salary of $112,988.

Compare Daiichi Sankyo salaries vs competitors

CompanyAverage salaryHourly salarySalary score
Daiichi Sankyo
$82,543$39.68-
American Regent
$59,872$28.78-
PDI
$64,390$30.96-
Organon
$73,941$35.55-
Endo Pharmaceuticals Inc
$78,978$37.97-
Pharmacia
$76,833$36.94-

Compare Daiichi Sankyo job title salaries vs competitors

CompanyHighest salaryHourly salary
Daiichi Sankyo
$35,483$17.06
Boehringer Ingelheim
$45,884$22.06
AstraZeneca
$45,381$21.82
Janssen
$44,994$21.63
Pernix Therapeutics Holdings
$40,618$19.53
Avion Pharmaceuticals
$40,301$19.38
Warner Chilcott
$40,217$19.34
Forest Pharmaceuticals Inc
$36,773$17.68
Santarus
$36,516$17.56
Brad Pharm
$36,166$17.39
Sanofi US
$35,946$17.28
Takeda Pharmaceuticals U.S.A., Inc.
$35,941$17.28
Xanodyne Pharmaceuticals
$35,659$17.14
Endo Pharmaceuticals Inc
$35,616$17.12
Organon
$35,480$17.06
Meda in the US
$35,455$17.05
Pharmacia
$35,343$16.99
Depomed
$35,320$16.98
PDI
$35,234$16.94
UCB
$35,226$16.94

Do you work at Daiichi Sankyo?

Is Daiichi Sankyo able to compete effectively with similar companies?

Daiichi Sankyo jobs

Daiichi Sankyo demographics vs competitors

Compare gender at Daiichi Sankyo vs competitors

Job titleMaleFemale
UCB47%53%
Takeda Pharmaceuticals U.S.A., Inc.49%51%
Daiichi Sankyo51%49%
AstraZeneca52%48%
Endo Pharmaceuticals Inc52%48%
Sanofi US53%47%

Compare race at Daiichi Sankyo vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
60%15%11%10%4%
9.5
60%13%11%12%4%
9.8
60%13%12%11%4%
9.8
59%14%11%12%4%
9.9
61%13%11%12%4%
9.7
59%13%15%10%4%
9.8

Daiichi Sankyo and similar companies CEOs

CEOBio
Dan Peisert
Depomed

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.

Pascal Soriot
AstraZeneca

Mark Morse
Pharmacia

Paul Hudson
Sanofi US

Roger Boissonneault
Warner Chilcott

Daniel Glassman
Brad Pharm

Jean-Christophe Tellier
UCB

Jean-Christophe Tellier joined UCB in 2011. He became UCB’s Chief Executive Officer on January 1, 2015 after having successfully led UCB’s BioBrands and Solutions division as Executive Vice President. He is a member of the Board of Directors of UCB, President of the Board of the European Federation of Pharmaceutical Associations (EFPIA), a member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America) and a member of the Board of WELBIO (Walloon Institute for Life Lead Sciences). Jean-Christophe Tellier is an experienced global leader. He was trained as a Medical Doctor and specialized in rheumatology. He has built a distinguished 30-year career in the biopharmaceutical industry, taking on different global leadership responsibilities in different parts of the world. His patient-centric approach, his passion for science, combined with his strategic and operational skills, have allowed him to significantly contribute to UCB’s success in recent years. For Jean-Christophe “engaging the patient in our vision is the best way for our company to be successful in the long term. Having a holistic view of a patient, of his/her life in his/her environment is essential to ensure effective treatment”. Jean-Christophe also believes that “all healthcare players - physicians, payors, carers, industry and academia - should cooperate even more effectively and become stronger partners sharing a same goal: improving patient care”. As a leader, Jean-Christophe has always had a passion for developing people, which he sees as “a key force to drive company success”. His ambition is to continue to further engage UCB teams behind the company’s vision and fully leverage UCB’s strong culture and talents

Jimmy Frangis
PDI

Daiichi Sankyo competitors FAQs

Search for jobs